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Abstract 
T cell activation requires engagement of the T cell receptor and of at least one 
costimulatory molecule. The key role of CD28 in inducing T cell activation has been 
reported several decades ago and the molecular mechanisms involved well described. 
The complement regulator CD46 also acts as a costimulatory molecule for T cells but, 
in contrast to CD28, has the ability to drive T cell differentiation from producing 
some IFN to secreting some potent anti-inflammatory IL-10, acquiring a so-called 
Type I regulatory phenotype (Tr1). Proteolytic cleavage of CD46 occurs upon 
costimulation and is important for T cell activation and IL-10 production. The 
observation that CD46 cleavage was reduced when PBMC were costimulated 
compared to purified naive T cells led us to hypothesize that interactions between 
different cell types within the PBMC were able to modulate the CD46 pathway. We 
show that CD46 downregulation is also reduced when CD4+ T cells are co-cultured 
with autologous monocytes. Indeed, monocyte:T cell co-cultures impaired CD46–
mediated T cell differentiation and coactivation, by reducing downregulation of 
surface CD46, lowering induction of the early activation marker CD69, as well as 
reducing the levels of IL-10 secretion. Blocking of CD86 could partly restore CD69 
expression and cytokine secretion, demonstrating that the CD28-CD86 pathway 
regulates CD46 activation. Direct concomitant ligation of CD28 and CD46 on CD4+ 
T cells also modulated CD46 expression and regulated cytokine production. These 
data identify a crosstalk between two main costimulatory pathways and provide novel 
insights into the regulation of human T cell activation.  
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Introduction 
 
T cell activation results from a complex integration of signals conjointly received by 
the TCR and additional costimulatory molecules. It involves, at least, a two-signal 
stimulation process. Signal 1 requires TCR ligation, which ensures the antigen 
specificity of the response and signal 2, or the costimulatory signal, is required to 
fully activate T cells. Further signals such as cytokines or alternate surface receptor 
also contribute to T cell activation. CD28, a member of the B7 family, is the main 
costimulatory molecule 1, 2. However, additional costimulatory molecules fulfilling 
the role of signal 2 have been described, although their specific role hasn’t been fully 
elucidated. Among these, CD46 was initially identified as a regulator for complement 
activity, binding to C3b and C4b complement and promoting their cleavage by factor 
I, hence protecting the cells from complement damage 3, 4. CD46 also binds to several 
pathogens 5-7. A role in the adaptive immune response was also later described, as 
costimulation with CD3/CD46 led to increased T cell proliferation 8, 9, induced 
morphological changes 10, affected T cell polarity 11 and, importantly, promoted a 
switch from Th1 to Tr1 Treg differentiation on addition of IL-2 12. This was 
characterized by secretion of high amounts of IL-10 12 and granzyme B 13. This 
regulatory pathway is altered in a number of chronic inflammatory diseases such as 
multiple sclerosis, rheumatoid arthritis and asthma, as IL-10 production upon CD46 
costimulation is impaired 14-19. This underlines the importance of the pathway for 
correct immune homeostasis. Importantly, CD46 expression is different between mice 
and men as CD46 is confined to the testis in mice while being ubiquitously expressed 
by human cells. Expression of human CD46 in transgenic mice however showed that 
CD46 has immunoregulatory properties in these mice 9. 
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CD46 is a type I membrane protein expressed by all human nucleated cells. CD46 
ectodomain is composed of four short consensus repeats and a region rich in serine, 
threonine and proline. This is followed by a transmembrane segment and a short 
cytoplasmic tail. Due to alternative splicing, multiple isoforms are produced, that 
include two distinct intracytoplasmic tails 20. In vitro studies using primary human T 
cells showed the antagonistic effects of CD46 cytoplasmic tails in T cell activation 
and cytokine production 21, 22. These studies also illustrated the importance of CD46 
processing for its function. Activation of CD46 on primary T cells led to its enzymatic 
processing, its ectodomain being partly cleaved by matrix-metalloproteinase (MMP), 
followed by the cleavage of its two cytoplasmic tails. Notably, inhibition of MMPs 
led to decreased IL-10 production by CD46 costimulated T cells. Moreover, CD46 
tail processing allows T cell activation but also T cell termination, and therefore is 
key to ensure T cell homeostasis 21, 22. Expression of CD46 at the surface of T cells is 
furthermore regulated by a variety of mediators, such as vitamin D 23 and 
prostaglandin E2 24. Together, these data underline the importance of the regulation of 
CD46 expression on activated T cells for T cell function. 
Herein, we first report the differential levels of CD46 downregulation on 
activated PBMC versus purified CD4+ T cells, which could be reproduced by co-
culture of purified monocytes and T cells. By dissecting the mechanisms involved, we 
have identified that CD28 controlled the CD46 pathway in activated human T cells, 
which notably modulated secretion of IL-10. Overall, we demonstrate a crosstalk 
between CD28 and CD46 that regulates CD46 expression and function, providing 
novel insights on the regulation of human T cell activation. 
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Results 
Reduced downregulation of CD46 on costimulated T cells in the presence of 
monocytes. 
CD46 is enzymatically processed upon CD3/CD46 costimulation. Notably, 
CD3/CD46 costimulation induces the MMP-dependent shedding of its ectodomain, 
leading to a strong downregulation of CD46 surface expression 21. In our previously 
published data, most of the experiments were conducted using highly purified CD4+ T 
cells. We therefore first compared levels of CD46 downregulation in cultured purified 
CD4+ T cells (>95% purity) and PBMC. PBMC were isolated from blood and CD4+ T 
cells purified from PBMC, keeping some PBMC for comparison. Cells were then 
activated in vitro by immobilized anti-CD3 and anti-CD3/CD46 antibodies for 2 days 
and CD46 expression assessed. As expected, a significant downregulation of CD46 
expression was observed on costimulated CD4+ T cells. However, CD46 
downregulation was much reduced on the lymphocyte gate when PBMC were 
analyzed (Figure 1a and 1b). As monocytes constitute the main population in PBMC 
susceptible to interact with T cells, we hypothesized that the difference in CD46 
expression between purified T cells and PBMC might be due to the interaction 
between monocytes and T cells. We therefore isolated CD14+ monocytes as well as 
autologous CD4+ T cells from PBMC (Figure 1c), and compared CD46 expression on 
costimulated T cells activated in the presence or absence of purified monocytes 
(Figure 1d). As expected, there was significant CD46 downregulation in purified 
CD4+ T cells (top panel), but also on monocytes activated by anti-CD46, suggesting 
that shedding of CD46 also occurs in monocytes. In contrast, we observed that co-
culture of monocytes and T cells significantly reduced CD46 downregulation, albeit 
only in CD4+ T cells. Similar data were obtained when we gated T cells using an anti-
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CD3 that specifically stained T cells and not the monocytes, or when we gated out the 
monocytes using an anti-HLA-DR or CD14 marker that did not stain T cells (Figure e 
and not shown). These data indicate that the co-culture of monocytes and T cells 
modulates CD46 expression on activated T cells.  
 
Co-culture of CD4+ T cells and monocytes modulates T cell phenotype. 
We next determined whether co-culture with monocytes also affected the phenotype 
of these T cells. We assessed expression of the two markers of activation, CD69 and 
CD25, after 2 or 5 days of culture (Figure 2). As expected, a strong upregulation of 
CD69 and CD25 was detected after CD3/CD46 costimulation of CD4+ T cells. 
Although T cells co-cultured with monocytes were activated and expressed high 
levels of CD25, they did not sustain CD69 expression after 5 days of culture, 
compared to purified T cells. As expected, an increase in CD69 and CD25 expression 
was detected for T cells activated by CD3 in the presence of monocytes.  Therefore, 
these data indicate that co-culture of purified T cells with monocytes cells did not 
affect T cell activation as CD25 expression was enhanced, but that it partially 
impaired CD46 downregulation and costimulated T cells did not sustain expression of 
CD69.   
 
Co-culture of monocytes and T cells affects cytokine production. 
One of the main outcomes of CD46 costimulation for human T cells is their switch 
from producing IFN to secreting IL-10, in the presence of IL-2 12. Thus, CD46 
costimulation can promote a regulatory phenotype by increasing the IL-10:IFN ratio 
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16, and CD46 processing is an important step in the release of IL-10 21. As we 
observed a lower downregulation of CD46 expression in the co-culture conditions, we 
hypothesized that it would affect production of these two cytokines, and assessed their 
levels. CD4+ T cells were activated by anti-CD3 or anti-CD3/CD46 in the presence or 
absence of monocytes and the levels of IL-10 and IFN were determined by ELISA 
after 4 days (Figure 3a). Co-culture conditions led to an increase in IFN production. 
As expected, a higher IL-10:IFN ratio was obtained for CD46-costimulated T cells 
compared to CD3-activated T cells (Figure 3b). However, this ratio was significantly 
lowered in the presence of monocytes, and addition of monocytes also reduced this 
ratio for CD3-activated T cells. Cytokines are mainly produced by the proliferating T 
cells after 5 days of culture, and we did not detect any significant levels of cytokines 
in the supernatants of monocytes cultured alone (not shown).  However, as monocytes 
can produce some IL-10, we could not exclude that monocytes secreted some 
cytokines in the co-culture conditions. Hence, we also assessed cytokine production 
by secretion assays on CD3+ gated T cells. As expected, CD46 costimulation of CD4+ 
T cells enhanced IL-10 secretion compared to CD3 activation. Co-culture with 
monocytes strongly decreased IL-10 secretion and increased IFN production by 
activated T cells (Figure 3c). Proliferation was also examined by staining the CD4+ T 
cells with eFluor® 670 before activation in the presence or absence of monocytes. 
While addition of monocytes promoted proliferation of T cells activated by CD3, 
there was no significant effect on proliferation of costimulated T cells (Figure 3d), 
suggesting that the shift in cytokine production towards IFN detected by ELISA was 
not correlated to increased cell numbers for CD46-costimulated T cells. 
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The CD28:CD86 pathway is involved in modulating CD46 function in the co-culture 
experiments. 
We next hypothesized that monocytes were modulating T cells through their cognate 
CD86:CD28 interaction. CD28 activation on T cells is mediated by binding to CD80 
(B7-1)/CD86 (B7-2) expressed on antigen presenting cells. As unstimulated human 
monocytes do not express CD80 25, we therefore assessed the effect of blocking CD86 
using a blocking antibody, or an IgG1 control. We also determined whether CD80 
was induced by in vitro culture in our model. However, CD80 expression on the 
monocytes could not be detected, even after 3 days of co-culture (data not shown). 
Addition of a blocking anti-CD86 Ab increased expression of CD69 on co-cultured T 
cells (Figure 4a), and increased IL-10 production by costimulated T cells in the 
presence of monocytes (Figure 4b). As CD46 is key to control IL-10 production by 
activated T cells, these data suggest that CD28 may impact the CD46 pathway 
through its interaction with CD86 to modulate CD46 function in T cells. 
 
CD28 costimulation modulates CD46 surface expression on activated T cells 
To confirm the existence of a crosstalk between CD28 and CD46 on T cells, we next 
determined whether CD28 concomitant co-stimulation affected the levels of CD46 on 
costimulated T cells. Purified human CD4+ T cells were left unstimulated or were 
activated with anti-CD3, anti-CD3/anti-CD28, anti-CD3/anti-CD46 or anti-CD3/anti-
CD28/anti-CD46. CD46 surface expression was examined by flow cytometry after 2 
days (Figure 5a). As previously shown, CD3/CD46 costimulation induced a strong 
downregulation of CD46 surface expression. Concomitant coactivation by CD28 led 
to an enhanced residual expression of CD46, compared to cells costimulated by 
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CD3/CD46 alone. A similar effect of CD28 was observed after 2 and 4 days (not 
shown) and similar effects were also observed when another CD46 antibody was used 
(E4.3 clone, not shown). These data demonstrate that the CD28 pathway controls 
CD46 expression on activated T cells. We also observed that CD46 costimulation 
enhanced CD28 expression on T cells, but that concomitant CD28 and CD46 
activation reduces this CD28 induction (not shown). Altogether, this demonstrates a 
crosstalk between CD28 and CD46 that regulates their expression on activated T 
cells. 
Lastly, to confirm the importance of CD28 ligation for the modulation of CD46 
function, we compared cytokine production and proliferation of purified T cells after 
activation by anti-CD3/CD28, anti-CD3/CD46 or anti-CD3/CD46/CD28 (Figure 5b-
e). Costimulation of T cells with either CD28 or CD46 or both led to enhanced IL-10 
secretion compared to CD3 activation alone. Secretion of IFN was mainly induced 
when CD28 was co-engaged and, as previously reported, low levels of IFN were 
detected in CD46-costimulated T cell supernatants in absence of CD28 co-
stimulation. However, concomitant coactivation significantly enhanced IFN 
production. When the IL-10:IFN ratio was calculated, as expected, there was an 
increased IL-10 ratio upon CD46 costimulation, but this ratio was significantly 
decreased when CD28 was concomitantly activated, although still higher than upon 
engagement of CD28 alone. In contrast, we did not find any significant effect of 
CD28 on the CD46-mediated proliferation. These data show that engagement of 
CD28 and CD46 alters the response of the T cells compared to single coactivation, as 
CD28/CD46 costimulation, by controlling secretion of IL-10 and IFN promotes 
regulatory function compared to CD28 alone but decreases it when compared to 
CD46 activation alone. 
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Inhibition of MMPs has a stronger effect on CD28-CD46 costimulated T cells than 
CD46 costimulated T cells. 
CD46 is partially shed by MMPs upon CD46 costimulation and MMP cleavage is 
necessary for IL-10 production 21, 22. Hence, we next determined whether addition of a 
broad MMP inhibitor could restore CD46 surface expression of CD28/CD46 
costimulated T cells (Figure 6). MMP inhibition partly decreased CD46 shedding on 
CD46 costimulated T cells, as previously shown, but had a stronger effect on T cells 
concomitantly activated by CD28, indicating that CD28 effect on CD46 was 
principally mediated by MMPs. 
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Discussion 
 
T cells are at the heart of the immune response and their activation is precisely 
controlled by a variety of signals. Besides engagement of the TCR by the antigenic 
peptide, ligation of several surface receptors dictate the fate of the T cells, by 
controlling their proliferation and differentiation. Most studies have focused on one 
particular costimulatory or co-inhibitory receptor. Herein, we have identified a 
crosstalk between two of the main costimulatory molecules for human T cells, CD28 
and CD46. CD46 activation on human T cells leads to its proteolytic cleavage that is 
important for IL-10 secretion 21. Our data first show that the co-culture of monocytes 
and T cells modulates the CD46 pathway, by lowering CD46 downregulation and 
reducing IL-10 secretion while enhancing IFN production. A crosstalk between 
monocytes and human  T cells has been previously reported 26. Moreover, a recent 
study has shown that interaction of activated monocytes with CD25+Foxp3+ 
regulatory T cells could modulate their cytokine production upon CD3 activation, by 
increasing production of both pro-inflammatory IFN and IL-17 and of anti-
inflammatory IL-10, and they remained suppressive 27. Our study shows that resting 
monocytes have the ability to modulate T cell activation, including the CD46 
pathway, although it is possible that monocytes undergo a slight differentiation after 
plating them into culture wells. It was previously published that human monocytes 
can upregulate CD80 during in vitro cultures 25. However, Dewar et al reported that 
monocytes cultured for 5 days in the presence of M-CSF or GM-CSF did not express 
CD80 28, and we were not able to detect CD80 in our system. By using a blocking 
antibody, we show that the interaction between CD86 and CD28 is at least partially 
responsible for this effect, although it is likely that other interactions are involved as 
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well. Moreover, direct antibody ligation of CD28 also down-modulates the regulatory 
functions of CD46, by reducing its downregulation and promoting IFN production. 
Regulation of the MMP/ADAM involved in cleaving CD46 ectodomain may 
therefore be regulated by CD28. It is therefore possible that CD28 stimulation alters 
levels of MMPs/ADAM involved in the shedding of CD46, which is supported by the 
fact that MMP inhibition further enhanced CD46 expression on CD28/CD46 
costimulated T cells.  
Although CD46 was initially described as a complement regulator, it has 
become apparent that it also modulates the adaptive immune response, by inducing T 
cell activation and differentiation, as well as influencing inflammation and 
modulating T cell polarity 8-10, 12, 29. The importance of CD46 function in T cells has 
been further evidenced by its plasticity in the regulation of T cell activation and/or 
differentiation, and overall T cell homeostasis 16, 21, 29, 30. Most importantly, it is now 
clear that CD46 costimulation on primary CD4+ T cells induces the secretion of the 
anti-inflammatory cytokine IL-10, while lowering IFN production 12, 16. Strikingly, 
this regulatory pathway is dysregulated in a number of pathologies (MS, RA and 
asthma), which again underlines the key role of CD46 in the control of inflammation 
15-19. Hence, the understanding of the mechanisms regulating CD46 expression and 
function in primary human T cells is key to fully comprehend how to regulate 
inflammation. The identification of the CD28/CD46 crosstalk may furthermore shed 
light on the defective CD46 pathway observed in MS, as increased expression of 
CD28 has been observed on MS T cells 31 and, therefore, this increased CD28 
expression may reduce CD46 regulatory functions in MS T cells. 
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The question of the ligands involved in this context is therefore critical, in 
other words, what engages CD46 in an APC:T cell interaction. CD3-activated T cells 
release some C3b, an endogenous ligand for CD46 16, 32. Therefore this likely 
provokes the necessary stimulus required to stimulate CD46. Moreover, this may also 
explain some of the observed effects on CD3-activated T cells. Finally, the local C3b 
produced may also feedback to the monocytes, and we have observed that CD46 
ligation of monocytes could affect their phenotype (unpublished data). Timing of the 
different activation pathways may also be important for the T cell in deciding whether 
to favor activation and / or regulation. It has been previously reported that CD28 was 
critical for initial T cell expansion, while 4-1BB had a later effect in the response 
being essential for the survival and/or responsiveness of memory CD8 T cells 33 and 
this differential effect was due to a switch in costimulation from CD28 to 4.1BB 34. 
Therefore, similar timing engagement of CD28 versus CD46 in human T cell 
activation may occur for human T cells. Naïve T cells are likely first activated by 
CD3/CD28, producing some C3b subsequently engaging CD46, which may switch 
the response to regulation. Lastly, memory T cells that have increased CD46 
expression compared to naive CD4+ T cells (unpublished data) require less 
costimulation than naïve T cells, suggesting that CD46 may play a preponderant role 
in memory T cells. Of note, we have also co-cultured monocytes with naïve T cells, 
and similar trends on T cell activation were observed (not shown). Moreover, CD46 
could have a key role in tolerance, and targeting the CD46 pathway in peptide 
induced tolerance (PIT) 35 may prove to be a beneficial approach, further enhancing 
tolerance through regulation of IL-10 secretion. Targeting of CD46 could be achieved 
by using recombinant proteins derived from adenovirus Ad35, as recently reported 36. 
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Altogether, the existence of a crosstalk between CD28 and CD46 highlights 
the complexity of the control of human T cell activation, and understanding the 
molecular mechanisms involved in T cell plasticity may provide novel therapeutics 
approach to restore immune homeostasis. 
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Methods 
 
Cell purification and activation: PBMC were isolated by Ficoll-Hypaque density 
gradient centrifugation (Pharmacia LKB Biotechnology, Piscataway, NJ), from 
citrated (0.38%) venous blood from healthy donors obtained after informed 
consent, and ethical approval from the NHS Lothian Board, and conformed to the 
provisions of the Declaration of Helsinki. CD4+ T cells were negatively isolated 
using magnetic beads (StemCell, purification > 97%), Monocytes were purified 
by CD14+ positive selection (StemCell, purifity >90%). Cells were cultured in 
RPMI 1640 with 10% fetal calf serum at 1x106 per well in 48-well plate pre-
coated with anti-CD3 (OKT3, 5µg/ml), anti-CD46 (MC120.6, 10 µg/ml kindly 
provided by Dr. Chantal Rabourdin-Combe, recognizing the SCR1 domain of 
CD46) or anti-CD28 (28.2, Ebiosciences, 5µg/ml). Activated primary T cells also 
received rhIL-2 (Life Technologies - 10U/ml). Co-cultures were performed by 
adding 0.2 million of monocytes followed by 0.2 million of T cells per well. For 
the blocking experiments, a blocking anti-CD86 (LEAF Purified anti-CD86, clone 
IT 2.2, 10 µg/ml, Biolegend) or irrelevant IgG1 (LEAF Purified IgG1, clone 
MODC21, 10 µg/ml) was added to the culture. 
Cytokine detection: Cell culture supernatants from the 48-well plates (as described 
in the cell activation section) were collected after five days of stimulation, and 
both IL-10 and IFN secretion was determined by ELISA specific for human IL-
10 (BD Pharmingen, San Diego, CA) and IFN  (Endogen, Rockford, IL).  
Alternatively, cytokine secretion was also determined using the IL-10 and IFN 
secretion assays from Miltenyi using anti-IFN-FITC and anti-IL-10-PE detection 
reagents, according to the manufacturer’s instructions and cells were gated on 
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CD3-APC+ T cells. Gates were done using the unstimulated T cells and were also 
verified using unstained activated T cells. 
Flow cytometry. The expression level of CD46, CD69 and CD25 was assessed by 
flow cytometry, by incubating the cells with the antibodies at 4°C for 20 min in 
FACS buffer (PBS containing 1% fetal calf serum). We used anti-CD46-FITC 
(clone MEM-258 – Biolegend, recognizing the SCR4 domain of CD46, hence a 
different domain that the stimulating antibody), anti-CD69-FITC (Biolegend) and 
anti-CD25-APC (Biolegend). In some instances, we also stained the cells with 
CD3-APC or CD28-PE, or CD14-APC to gate the cells. Samples were run with a 
FACSCalibur and data analyzed using FlowJo. Relative expression to staining 
with the control was calculated by calculating the MFI (MFI obtained with 
antibody - MFI obtained with isotype control).  
Proliferation assay: Proliferation was determined by pre-labeling purified T cells 
with eFluor 670 cell proliferation stain (eBioscience) before activation following 
the manufacturer’s instructions, and assessing remaining fluorescence after 4 
days. In some experiments, CD4+ T cells were plated in duplicate at 5x104 in a 
pre-coated 96 well-plate as described above. After three days stimulation at 37oC, 
cells were pulsed with 1µCi of [3H]thymidine (Amersham) and cultured for 18hrs. 
Proliferation was then determined using a Liquid Scintillation Counter (Wallac, 
Boston, USA). 
Statistics. The groups were analyzed using Graphpad Prism software. Flow 
cytometry data were analyzed using the Wilcoxon test, when assessing paired 
samples. ELISA data are the average of duplicate wells, and the average obtained 
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for the different donors were analyzed using the Wilcoxon test. All p-values are 
two-tailed and with a 95% confidence interval. 
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Figure Legends 
 
Figure 1. Reduced downregulation of CD46 on T cells in activated 
PBMCs and CD4+ T cell:monocyte co-cultures compared to purified 
CD4+ T cells. (a) PBMC (tinted grey histograms) or purified CD4+ T cells 
(black histograms) were left unstimulated (US) or were activated by 
immobilized anti-CD3 and anti-CD46 for 2 days and CD46 expression 
analyzed by flow cytometry. The MFI of the stained samples are indicated 
for CD4+ T cells (in black) and PBMC (in grey). Dashed line = isotype 
control. Representative plots shown. (b) The percentage of remaining 
surface CD46 was calculated for CD46-costimulated PBMC and CD4+ T 
cells (n=5, mean +/- SEM). (c) CD4+ T cells and CD14+ monocytes were 
purified and co-cultured and (d) expression of CD46 was determined after 
2 days. The MFI obtained for CD46 (in black) and for the isotype (in grey) 
are indicated. Representative of 3 donors. Staining using DR and CD3 is 
shown in (e). 
 
Figure 2. CD4+ T cell:monocyte co-cultures modulate T cell phenotype. 
Purified CD4+ T cells cultured alone or in the presence of autologous 
monocytes were left unstimulated (US) or were activated by immobilized 
anti-CD3 and anti-CD46 for (a) 2 or (b) 5 days, and expression of CD46, 
CD69 and CD25 was determined by flow cytometry on the lymphocyte 
population gated by size (mean +/- SEM).  
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Figure 3. CD4+ T cell:monocyte co-cultures modulate IL-10 and IFN 
production by activated T cells. (a) The production of IL-10 and IFN in 
the culture supernatants of activated purified T cells or CD4+ T 
cells:monocyte co-cultures at day 4 was assessed by ELISA (n=5; mean +/- 
SEM). (b) The IL-10:IFN ratio is also represented. (c) IL-10 and IFN 
secretion of CD3+ gated T cells cultured in the presence or absence of 
monocytes was assessed by secretion assays. (d) Purified CD4+ T cells 
were pre-labeled with eFluor 670 before activation by immobilized anti-
CD3 or anti-CD3/anti-CD46 in the presence or absence of monocytes. Four 
days later, proliferation was monitored by flow cytometry. 
 
Figure 4. Blocking CD86 in CD4+ T cell:monocyte cocultures enhances 
CD69 expression and IL-10 production by activated T cells. (a) CD4+ T 
cells were activated with autologous monocytes by immobilized anti-CD3 
and/or anti-CD46 in the presence of a blocking anti-CD86 antibody (black 
histograms) or irrelevant IgG1 control (tinted grey histograms). CD69 
surface expression was then monitored by flow cytometry. 2 donors are 
shown (out of n=4). (b) Production of IL-10 and IFN were assessed after 4 
days by secretion assays. 
 
Figure 5. Concomitant CD28 and CD46 ligations modulate cytokine 
production. Purified CD4+ T cells were left unstimulated (US), or were 
activated by immobilized anti-CD3 alone or in addition of anti-CD28 
and/or anti-CD46 antibodies, as indicated. (a) Expression of CD46 was 
determined after 2 days. Dashed line = isotype control. The MFI obtained 
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for CD46 are indicated. The production of IL-10 (b) and IFN (c) in the 
culture supernatants of activated purified T cells was determined by ELISA 
(n=14). (d) The IL-10:IFN ratio is also represented for costimulated T 
cells. (e) Proliferation was monitored by thymidine incorporation. Mean +/- 
SEM is represented.  
 
Figure 6. MMP inhibition results into increased surface CD46 
expression on CD28/CD46 costimulated T cells. CD4+ T cells were 
activated with immobilized antibodies as indicated in presence or absence 
of GM6001, a broad metalloproteinase inhibitor (10 M). After 2 days, the 
cell surface expression of CD46 was determined by flow cytometry. 
Dashed line = isotype control. (a) shows the representative plots obtained 
for one donor, and (b) shows the data obtained for the different donors 
(n=8; mean +/- SEM). 
 
 
